** Shares of PTC Therapeutics PTCT.O fall 1.3% to $45.43 in morning trade
** Company, late on Tuesday, said it has discontinued development of its experimental drug to treat amyotrophic lateral sclerosis (ALS)
** The drug, utreloxastat, failed to slow disease progression, the main goal, in a mid-stage trial - PTCT
** "While this outcome is unfortunate, expectations were low given that drug development in ALS has been difficult and supporting evidence for utreloxastat in ALS was limited" - TD Cowen analysts
** ALS is a rare neurological disease that can break down nerve cells, in the brain and spinal cord, responsible for muscle movements
** Including session moves, stock up about 64% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。